Literature DB >> 35284514

Editorial comment on: "Systemic treatment of hepatocellular carcinoma: an EASL position paper".

Daniel H Ahn1, Tanios Bekaii-Saab1.   

Abstract

Entities:  

Year:  2022        PMID: 35284514      PMCID: PMC8847863          DOI: 10.21037/hbsn-21-469

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  9 in total

1.  Cabozantinib in Hepatocellular Carcinoma.

Authors:  Ghassan K Abou-Alfa; Anne E Borgman-Hagey; Robin K Kelley
Journal:  N Engl J Med       Date:  2018-10-04       Impact factor: 91.245

2.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.

Authors:  Masatoshi Kudo; Richard S Finn; Shukui Qin; Kwang-Hyub Han; Kenji Ikeda; Fabio Piscaglia; Ari Baron; Joong-Won Park; Guohong Han; Jacek Jassem; Jean Frederic Blanc; Arndt Vogel; Dmitry Komov; T R Jeffry Evans; Carlos Lopez; Corina Dutcus; Matthew Guo; Kenichi Saito; Silvija Kraljevic; Toshiyuki Tamai; Min Ren; Ann-Lii Cheng
Journal:  Lancet       Date:  2018-03-24       Impact factor: 79.321

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

4.  Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.

Authors:  L Zhou; X-D Liu; M Sun; X Zhang; P German; S Bai; Z Ding; N Tannir; C G Wood; S F Matin; J A Karam; P Tamboli; K Sircar; P Rao; E B Rankin; D A Laird; A G Hoang; C L Walker; A J Giaccia; E Jonasch
Journal:  Oncogene       Date:  2015-09-14       Impact factor: 9.867

5.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Jordi Bruix; Shukui Qin; Philippe Merle; Alessandro Granito; Yi-Hsiang Huang; György Bodoky; Marc Pracht; Osamu Yokosuka; Olivier Rosmorduc; Valeriy Breder; René Gerolami; Gianluca Masi; Paul J Ross; Tianqiang Song; Jean-Pierre Bronowicki; Isabelle Ollivier-Hourmand; Masatoshi Kudo; Ann-Lii Cheng; Josep M Llovet; Richard S Finn; Marie-Aude LeBerre; Annette Baumhauer; Gerold Meinhardt; Guohong Han
Journal:  Lancet       Date:  2016-12-06       Impact factor: 79.321

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

8.  Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.

Authors:  Takahito Hara; Akiko Kimura; Tohru Miyazaki; Hiroshi Tanaka; Megumi Morimoto; Katsuhiko Nakai; Junpei Soeda
Journal:  Biochem Biophys Rep       Date:  2020-01-17

9.  Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.

Authors:  Mohamad Bassam Sonbol; Irbaz Bin Riaz; Syed Arsalan Ahmed Naqvi; Daniel R Almquist; Syeda Mina; Jehad Almasri; Shiv Shah; Diana Almader-Douglas; Pedro Luiz Serrano Uson Junior; Amit Mahipal; Wen Wee Ma; Zhaohui Jin; Kabir Mody; Jason Starr; Mitesh J Borad; Daniel H Ahn; M Hassan Murad; Tanios Bekaii-Saab
Journal:  JAMA Oncol       Date:  2020-12-10       Impact factor: 31.777

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.